Advancing the Cardiovascular Care of the Oncology Patient

Advancing the Cardiovascular Care of the Oncology Patient

COURSE OVERVIEW/STATEMENT OF NEED
Cardiovascular disease is the second leading cause of morbidity and mortality in cancer survivors. Since an estimated 14.5 million cancer patients and survivors have significant cardiovascular risk factors, it is critical for cardiologists, oncologists, and the entire multi-professional care team to stay on the leading edge of this rapidly evolving field. Advancing the Cardiovascular Care of the Oncology Patient provides clinicians and researchers with the tools needed to improve patient care in your everyday practice.

Over the past 4 years, the American College of Cardiology has joined forces with respected experts in the field of Cardio-oncology to develop a program covering the most relevant and required content for both the novice and advancing practitioner. Join us at Advancing the Cardiovascular Care of the Oncology Patient and engage with our growing community. Participate through interactive case discussions on evidence-based treatment strategies that address pre, intra and post-chemotherapy heart health. Throughout the course, you'll have the unique opportunity to engage with expert faculty and a network of colleagues centered around ensuring your patients receive the most informed care possible.

Goal
The overall goal of this course is to provide clinically relevant, state-of-the-art, best practice strategies for the interprofessional team in the assessment, diagnosis and management of cardiovascular concerns for patients with cancer and/or those requiring survivorship care.

Learning Objectives
Upon completion of this course, learners should be able to —

  • Discuss the mechanisms of action as it relates to both oncologic efficacy and cardiotoxicity of common cancer treatment therapies and the resultant impact on cardiovascular disease
  • Review the appropriate imaging modalities to assess cardiotoxicity, distinguish the strengths and weaknesses of the respective modalities available, and the optimal approach to long term surveillance
  • Summarize guidelines from the cardiology and oncology societies for risk stratification, monitoring strategies, and management, and identify action steps to incorporate guidance into clinical practice
  • Evaluate best practices for understanding coronary disease, vascular toxicities – including hypertension and peripheral arterial disease, and bleeding/thrombosis in cancer patients
  • Analyze the short and long-term surveillance and management plans critical for patients who have received high-risk systemic therapies, including androgen deprivation therapy, thoracic radiation therapy and anthracyclines
  • Identify best practices for developing cardio-oncology service lines and building the inter-professional cardio-oncology team needed for success
  • Recognize the pathologic basis for amyloid, diagnostic workup and also treatment strategies

Target Audience
The target audience is cardiovascular specialists, oncologists, internists, and all members of the multi-professional care team (including advanced practice providers, pharmacists, nurses) who are providing clinical care to the growing population of cancer patients and survivors with cardiovascular concerns.

Course Directors

Ana Barac, MD, PhD, FACC
Medstar Washington Hospital Center

Bonnie Ky, MD, MSCE, FACC
University of Pennsylvania School of Medicine

Planning Committee

Rachel Barish, MSN, ANP-BC, AACC
Medstar Georgetown Physicians Group

Christine Cambareri, PharmD, BCPS, BCOP
Hospital of the University of Pennsylvania

Nurse Planner

Chris Keenan, RN, MSN
American College of Cardiology

Keynote Speaker

Richard J. Kovacs, MD, FACC
President, American College of Cardiology

Faculty

Saro Armenian, DO, MPH
City of Hope Comprehensive Cancer Center

Jean-Bernard Durand, MD, FACC, FCCP, FHFSA, FAHA
University of Texas

Steven Joel Feigenberg, MD
Hospital of the University of Pennsylvania

Michael Fradley, MD
University of South Florida

Daniel J. Lenihan, MD, FACC
Washington University School of Medicine in St. Louis

Filipa Lynce, MD
Georgetown University

Chiara Melloni, MD, MHS, FACC
Duke University

Iskra Pusic, MD, MSCI
Washington University School of Medicine

Mohammad Shahsahebi, MD
Duke University

Paaladinesh Thavendiranathan, MD
Institute of Medical Science
University of Toronto

Ronald Witteles, MD, FACC
Stanford University School of Medicine

Faculty are subject to change without notice.

CONFLICT OF INTEREST (COI) POLICY/DISCLOSURES
ACCF committee members, faculty, staff and other individuals who are in a position to control the content of this activity are required to disclose all relevant financial relationships he/she and/or his/her spouse or domestic partner has, occurring within the past twelve months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations. Refer to the links below for committee member disclosures and course faculty disclosures. Please note ACCF staff involved with this course have nothing to disclose.

In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
The ACCF designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
The ACCF designates this educational activity for a maximum of 16.75 continuing nursing education contact hour(s).

Pharmacists
This activity is eligible for ACPE credit.

2020 Pre-conference Educational Seminar: Pharmacologic Review of Cancer Therapy Essentials

We will kick off Friday evening with an optional, limited-seating pre-conference entitled Pharmacologic Review of Cancer Therapy Essentials: Anthracyclines, Her2+ Targeted Therapy, Immunotherapy, Tyrosine Kinase Inhibitors, Proteasome Inhibitors.

Friday, February 14, 2020
4:00 p.m. – 6:30 p.m. at Heart House

Sold Out!

To Register online for the Course please click the Register button at the top of the page.

If you have any special Dietary requirements, please note that this is now captured through your online profile. To enable us to accommodate your request, please ensure that your profile is up to date. If you select the (other) option, a member of our team will be in touch to discuss your needs. If you require assistance, please contact the Resource Center at 800-253-4636, ext. 5603.

To Register by Fax or Ground Mail for the Course click here.

Please register me as: Designation   Early Before 10/24/19 Advanced 10/25/19 – 1/7/20  Regular 1/8/20 – 2/15/20
Member Physician (includes International Associate)
MD, DO, PhD $600
$700
$800
Non-member Physician
MD, DO, PhD $800
$900
$1,000
AACC/CCA Member - Includes CVT Member, FIT, Resident, Student and Emeritus
PA, RN, NP, CNS, PharmD, FIT, Resident, Student and Emeritus
$400 $500
$600
CCA Non-member
PA, RN, NP, CNS, PharmD, FIT, Resident, Student
$500
$600
$700
Industry Professional
  $900
$1,000
$1,100

Tuition
The registration tuition includes educational sessions, continental breakfasts, refreshment breaks, lunch and course materials.

Cancellations
Cancellation, substitution or transfer to another course is allowed if written notification is received four weeks before a scheduled course. A full refund minus a $250 processing fee will be given for written notifications received fewer than four weeks before the first day of the course. No refund will be given for no-shows.

ACC reserves the right to cancel the course in the unlikely event of insufficient enrollment or other unforeseen circumstances. If a course is canceled or postponed, ACC will refund registration tuition but cannot be held responsible for other costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.

TRAVEL

Location:
The course will be held at The Ritz-Carlton, 1150 22nd Street, NW, Washington, DC 20037. The telephone number is 202-835-0500.

Accommodations

The ACC room block at The Ritz-Carlton is sold out. Below are nearby hotels that may have rooms available. Please contact them for their room rates and to make a reservation.

Thank you for your interest in submitting an abstract for Advancing the Cardiovascular Care of the Oncology Patient scheduled for February 14-16, 2020 in Washington, D.C.

Before submitting an abstract, please thoroughly review the abstract policies and procedures and submission instructions.

Submission
Submission of abstracts to Advancing the Cardiovascular Care of the Oncology Patient is now closed. Please contact Ryan Meyer at rmeyer@acc.org with any questions.

General Information

  • All abstract presentations will be in English. All abstracts will be presented as poster presentations on February 14-16, 2020.
  • Investigators do not need be ACC members to participate.
  • All accepted abstract presenters must register to obtain a meeting badge. Individuals should register in the appropriate category (member, nonmember, etc.) and pay the fees appropriate for that category.
  • ACC is unable to reimburse abstract presenters for travel, hotel, or per diem expenses.
  • General Information subject to change due to circumstances beyond the ACC's control.

Disposition/Notification of Acceptance

You will be sent a notification with the status of your submission via email by January 13, 2020. If accepted, you will be directed to provide disclosure and registration information.

Withdrawals

To withdraw an abstract, email Ryan Meyer at rmeyer@acc.org and provide the title of the abstract, as well as the primary author's name. Your notification of withdrawal must be received by January 20, 2020.

EMBARGO POLICY
ACC Advancing the Cardiovascular Care of the Oncology Patient Conference 2020 abstracts are embargoed until Friday, Feb. 14, 2020, at 9 a.m. ET. Therefore, authors/institutions and members of the press cannot distribute or publish any information (other than the title) from the abstract while the embargo is in effect. The ACC welcomes the participation of institutions in promoting research presented at the ACC Advancing the Cardiovascular Care of the Oncology Patient Conference 2020. All promotions must abide by the embargo date and time. For questions, please contact ACC Sr. Media Relations Associate Katie Glenn, kglenn@acc.org.

Clinical Topics: Cardio-Oncology

Keywords: Cardiotoxicity